August 2022 - Page 2 of 4 - BioMedWire (BMW)

TuesdayAug 23, 2022 11:35 am

Study Finds That Early Exposure to Antibiotics May Trigger Asthma, Permanent Allergies

A new study from Rutgers University has revealed that antibiotics can be a double-edged sword when used in early childhood. The study found that even though early exposure to antibiotics can be effective against bacterial infections in early childhood, they also kill off “good” bacteria in the digestive tract. Furthermore, the study found that early childhood exposure to antibiotics can also cause allergies and asthma later in life. The study, which published its findings in the “Mucosal Immunology” journal, adds to the growing body of research that indicates antibiotic exposure during the early childhood years is associated with the late…

MondayAug 22, 2022 12:01 pm

Report Details Most Prevalent Symptoms of Six Cardiovascular Illnesses

A scientific statement documenting the findings of a review conducted about the current scientific information available on the symptoms of different cardiovascular diseases has pointed out which symptoms are most common and how symptom presentation varies based on other factors, including age, sex and race, among others. One of the notable observations that the report makes is that it is important to move away from depending on only a physician’s assessment of symptom severity to relying more on self-reported symptom severity because the latter is a more reliable pointer of how serious the cardiovascular disease may be. Self-reported symptoms also…

MondayAug 22, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needs Recently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing (“SAD”) clinical trial The MAD arm thus far shows that the drug is safe and well tolerated Odyssey expects to report additional MAD results as they become available A few weeks after completing its Phase I Single Ascending Dosing (“SAD”) clinical trial, Odyssey Health (OTC:…

FridayAug 19, 2022 12:31 pm

Targeted Cancer Vaccines Show Promise in Halting Tumor Progression

As of 2020, an estimated 18.8 million people worldwide had cancer. The deadly disease takes millions of lives each year, with the United States losing more than 600,000 yearly to cancer deaths. Although scientists have worked tirelessly for years to develop a cure for cancer with little success, there are several treatments that can reduce the growth of the cancer and increase the lifespan of cancer patients. Efforts to develop cancer vaccines have been equally unsuccessful — that is until the Tufts School of Engineering revealed that it may have found a way to halt tumors in their tracks and prevent…

ThursdayAug 18, 2022 2:25 pm

Study Finds Vitamin D May Help Alleviate Depression Symptoms

A new study has found that supplementing using vitamin D may help alleviate symptoms of depression in adults suffering from the mental health condition. The study, which involved an extensive meta-analysis, was carried out by a global team of scientists and included numerous studies from various regions of the globe. Depression symptoms can cause substantial disease burden globally, which isn’t helped by the fact that many currently used antidepressants aren’t therapeutically effective. This is why alternative methods of relieving the symptoms of depression are being studied in nutritional research. Vitamin D is an important nutrient for the body, which helps…

WednesdayAug 17, 2022 12:23 pm

New Study Plans to Eliminate Side Effects of Cancer Therapies in Children

Around 1 in 285 children will develop some kind of cancer before they turn 20. Cancer is one of the deadliest disease that afflicts children and adolescents, taking an estimated 1,800 lives in the United States each year. Although scientists still haven’t developed a cure for cancer, there are a variety of treatments, including radiation, chemotherapy or surgery, that can attack fast-growing cancer cells and prevent them from growing. However, most pediatric cancer treatments come with a variety of side effects, with treatments such as chemotherapy inadvertently causing unwanted side effects, including fatigue, mucositis, endocrine dysfunction, neurocognitive impairment, neurotoxicity, nausea…

WednesdayAug 17, 2022 9:30 am

Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF

Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo in June, 2021 to “to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. “Successful dosing and collection of blood samples from enrolled patients is an important milestone that demonstrates the progress being made…

TuesdayAug 16, 2022 2:32 pm

Research to Examine Potential Link Between Concussions, Long COVID

The first case of COVID-19 was reported in Wuhan, China, in late 2019. In the following months, countries around the world shut down their borders as the virus infected millions of people. Although the virus had a high survival rate of more than 90% in the United States, thousands of patients across the country began reporting coronavirus symptoms that lasted more than two months. Christened long COVID, this condition left patients suffering from symptoms such as cognitive dysfunction, shortness of breath, headache, chest pain and fatigue for up to three months after they contracted COVID-19. According to a report from…

TuesdayAug 16, 2022 10:30 am

QSAM Biosciences Inc. (QSAM) Awarded Patent for Potential Breakthrough Bone Cancer Treatment

This is the third U.S. patent granted to QSAM, further strengthening its IP portfolio, which consists of 14 patents among three patent families. “CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer,” says QSAM CEO. Patent covers formulation and preparation of CycloSam in the U.S. QSAM Biosciences (OTCQB: QSAM) has been awarded a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R). Granted by the U.S. Patent & Trademark Office, the patent “protects how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to…

MondayAug 15, 2022 12:47 pm

Senate Review Reveals Screening Mistakes Caused Organ Transplant Failures, Illnesses, Deaths

There have been more than 25,000 organ transplants per year in the United States since the mid-2000s. On average, around 95 organ transplants are carried out in the country per day, with someone being added to the national organ transplant waiting list every nine minutes. Kidney transplants tend to have the highest post-transplant survival rate followed by liver, heart and lung transplants. A recent report from the Senate Finance Committee has revealed a disturbing fact: a lack of oversight in the organization charged with supervising organ testing and transplants in the country has led to dozens of cases of illness…